|
|
 |
| Press kit |
| Press Relese ERS Sept 2004 |
| Respimat® Soft Mist™ Inhaler (SMI) represents a major step forward in inhalation therapy, resulting in high patient preference and satisfaction over other devices, according to the results of an analysis presented on Sunday, September 5, 2004 in the thematic poster session "Primary Care: COPD" at the 14th Annual Congress of the European Respiratory Society in Glasgow, United Kingdom. |
|
|
| Need for new inhaler |
| Respimat® Soft Mist™ Inhaler: The need for a new inhaler device. The clinical success of a medication depends upon its efficacy, tolerability and, since compliance is a significant issue, its acceptability to patients. |
|
|
| New generation inhaler |
| Boehringer Ingelheim, with its experience in modern device technology coupled with extensive experience in the development of respiratory drugs, takes a significant step forward for inhaler therapy by launching the first Respimat® product, Berodual® Respimat®, in Germany in early 2004. |
|
|
| Technical background |
| Respimat® Soft Mist™ Inhaler (SMI), developed by Boehringer Ingelheim, is a propellant-free, new generation inhaler that represents a major step forward in inhalation therapy. |
|
|
| Boehringer's COPD activities |
| COPD is a major socio-economic burden, being among the top 5 causes of disability and death in industrial societies. In spite of its enormous burden to societies and the individual, and although there are potentially more COPD patients than asthma patients, COPD is widely under-diagnosed and mistreated for a variety of reasons. |
|
|
| Glossary |
|
|
|
| Respimat® Insight – the new generation inhaler |
 |
|
 |
| more ... |
| How to use |
|
|
 |
| Twist, press and breathe – it's that easy to use the Respimat® Soft Mist™ Inhaler. |
| more ... |
|
 |
